The role of BST2/tetherin in feline retrovirus infection

Veterinary Immunology and Immunopathology

Volumn 143, Issue 3-4, 2011, Pages 255-264

  Dietrich, Isabelle ^a   Hosie, Margaret J ^a   Willett, Brian J ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

Author keywords

Feline tetherin; FIV; Intrinsic immunity

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYDROLASE; MEMBRANE PROTEIN; PROTEIN TETHERIN; RETROVIRUS VECTOR; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUSION; CELL LINE; CELL SURFACE; CROSS LINKING; CYTOPLASM; DEAMINATION; DISEASE MODEL; DRUG ANTAGONISM; ENDOCYTOSIS; EXPERIMENTAL CAT; FELIDAE; FELINE LEUKEMIA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; LENTIVIRINAE; LION; NONHUMAN; PAN TROGLODYTES; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PUMA; RETROVIRUS; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; TRANS GOLGI NETWORK; UBIQUITINATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS RELEASE; VIRUS REPLICATION; VIRUS UNCOATING;

ANIMALS; CATS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNITY, INNATE; IMMUNODEFICIENCY VIRUS, FELINE; VIRUS REPLICATION;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; MIRIDAE; PRIMATES;

EID: 80052348493     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.06.020     Document Type: Short Survey

References (149)

1. Abada P., Noble B., Cannon P.M. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 2005, 79:3627-3638.
2. Ackley C.D., Yamamoto J.K., Levy N., Pedersen N.C., Cooper M.D. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J. Virol. 1990, 64:5652-5655.
3. Aguiar R.S., Peterlin B.M. APOBEC3 proteins and reverse transcription. Virus Res. 2008, 134:74-85.
4. Andrew A.J., Miyagi E., Kao S., Strebel K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009, 6:80.
5. Bendinelli M., Pistello M., Lombardi S., Poli A., Garzelli C., Matteucci D., Ceccherini-Nelli L., Malvaldi G., Tozzini F. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin. Microbiol. Rev. 1995, 8:87-112.
6. Benveniste R.E., Todaro G.J. Segregation of RD-114 AND FeLV-related sequences in crosses between domestic cat and leopard cat. Nature 1975, 257:506-508.
7. Bergeron J.R., Huthoff H., Veselkov D.A., Beavil R.L., Simpson P.J., Matthews S.J., Malim M.H., Sanderson M.R. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog. 2010, 6:e1000925.
8. Berthoux L., Sebastian S., Sokolskaja E., Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J. Virol. 2004, 78:11739-11750.
9. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 2004, 5:1109-1115.
10. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 2004, 14:1392-1396.
11. Bishop K.N., Holmes R.K., Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 2006, 80:8450-8458.
12. Blasius A.L., Giurisato E., Cella M., Schreiber R.D., Shaw A.S., Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 2006, 177:3260-3265.
13. Bour S., Schubert U., Strebel K. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J. Virol. 1995, 69:1510-1520.
14. Brown E.W., Miththapala S., O'Brien S.J. Prevalence of exposure to feline immunodeficiency virus in exotic felid species. J. Zoo Wildl. Med. 1993, 24:357-364.
15. Brown E.W., Yuhki N., Packer C., O'Brien S.J. A lion lentivirus related to feline immunodeficiency virus: epidemiologic and phylogenetic aspects. J. Virol. 1994, 68:5953-5968.
16. Callanan J.J., Thompson H., Toth S.R., O'Neil B., Lawrence C.E., Willett B.J., Jarrett O. Clinical and pathological findings in feline immunodeficiency virus experimental infection. Vet. Immunol. Immunopathol. 1992, 35:3-13.
17. Callanan J.J., Jones B.A., Irvine J., Willett B.J., McCandlish I.A.P., Jarrett O. Histological classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections. Vet. Pathol. 1996, 33:264-272.
18. Cao W., Boyer L., Cho M., Wen X., Hanabuchi S., Bao M., Rosen D.B., Wang Y.H., Shaw J.L., Du Q., Li C., Arai N., Yao Z., Lanier L.L., Liu Y.J. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 2009, 206:1603-1614.
19. Carpenter M.A., Brown E.W., Culver M., Johnson W.E., Pecon-Slattery J., Brousset D., O'Brien S.J. Genetic and phylogenetic divergence of feline immunodeficiency virus in the puma (Puma concolor). J. Virol. 1996, 70:6682-6693.
20. Cohen E.A., Terwilliger E.F., Sodroski J.G., Haseltine W.A. Identification of a protein encoded by the vpu gene of HIV-1. Nature 1988, 334:532-534.
21. Colonna M., Trinchieri G., Liu Y.L. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
22. Conticello S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008, 9:229.
23. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 2003, 13:2009-2013.
24. Conticello S.G., Langlois M.A., Yang Z., Neuberger M.S. DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv. Immunol. 2007, 94:37-73.
25. Courgnaud V., Abela B., Pourrut X., Mpoudi-Ngole E., Loul S., Delaporte E., Peeters M. Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different Cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J. Virol. 2003, 77:12523-12534.
26. Diaz-Griffero F., Li X., Javanbakht H., Song B., Welikala S., Stremlau M., Sodroski J. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 2006, 349:300-315.
27. Dietrich I., McMonagle E.L., Petit S., Logan N., Chan C.N., Towers G.J., Hosie M.J., Willett B.J. Feline tetherin efficiently restricts feline immunodeficiency virus release but not spreading infection. J. Virol. 2011, 85:5840-5852.
28. Douglas J.L., Viswanathan K., McCarroll M.N., Gustin J.K., Früh K., Moses A.V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 2009, 83:7931-7947.
29. Dube M., Roy B.B., Guiot-Guillain P., Mercier J., Binette J., Leung G., Cohen E.A. Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 2009, 83:4574-4590.
30. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987, 237:888-893.
31. Fitzpatrick K., Skasko M., Deerinck T.J., Crum J., Ellisman M.H., Guatelli J. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog. 2010, 6:e1000701.
32. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 1992, 66:6489-6495.
33. Goff S.P. Genetic control of retrovirus susceptibility in mammalian cells. Annu. Rev. Genet. 2004, 38:61-85.
34. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Kräusslich H.G., Fackler O.T., Keppler O.T. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5:285-297.
35. Goila-Gaur R., Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51.
36. Goto T., Kennel S.J., Abe M., Takishita M., Kosaka M., Solomon A., Saito S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994, 84:1922-1930.
37. Göttlinger H.G., Dorfman T., Cohen E.A., Haseltine W.A. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:7381-7385.
38. Gupta R.K., Mlcochova P., Pelchen-Matthews A., Petit S.J., Mattiuzzo G., Pillay D., Takeuchi Y., Marsh M., Towers G.J. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20889-20894.
39. Gupta R.K., Hué S., Schaller T., Verschoor E., Pillay D., Towers G.J. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 2009, 5:e1000443.
40. Guo F., Cen S., Niu M., Saadatmand J., Kleiman L. Inhibition of tRNA3Lys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 2006, 80:11710-11722.
41. Guo X., Ma J., Sun J., Gao G. The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:151-156.
42. Harris R.S., Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 2004, 4:868-877.
43. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809.
44. Hatziioannou T., Princiotta M., Piatak M., Yuan F., Zhang F., Lifson J.D., Bieniasz P.D. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 2006, 314:95.
45. Hinz A., Miguet N., Natrajan G., Usami Y., Yamanaka H., Renesto P., Hartlieb B., McCarthy A.A., Simorre J.P., Göttlinger H., Weissenhorn W. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 2010, 7:314-323.
46. Hofmann-Lehmann R., Fehr D., Grob M., Elgizoli M., Packer C., Martenson J.S., O'Brien S.J., Lutz H. Prevalence of antibodies to feline parvovirus, calicivirus, herpesvirus, coronavirus, and immunodeficiency virus and of feline leukemia virus antigen and the interrelationship of these viral infections in free-ranging lions in east Africa. Clin. Diagn. Lab. Immunol. 1996, 3:554-562.
47. Holmes R.K., Koning F.A., Bishop K.N., Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282:2587-2595.
48. Hosie M.J., Robertson C., Jarrett O. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom. Vet. Rec. 1989, 12:293-297.
49. Ishikawa J., Kaisho T., Tomizawa H., Lee B.O., Kobune Y., Inazaka J., Oritani K., Itoh M., Ochi T., Ishihara K. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995, 26:527-534.
50. Iwabu Y., Fujita H., Kinomoto M., Kaneko K., Ishizaka Y., Tanaka Y., Sata T., Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284:35060-35072.
51. Iwatani Y., Takeuchi H., Strebel K., Levin J.G. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 2006, 80:5992-6002.
52. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007, 35:7096-7108.
53. Jia B., Serra-Moreno R., Neidermyer W., Rahmberg A., Mackey J., Fofana I.B., Johnson W.E., Westmoreland S., Evans D.T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009, 5:e1000429.
54. Johnson W.E., Eizirik E., Pecon-Slattery J., Murphy W.J., Antunes A., Teeling E., O'Brien S.J. The late Miocene radiation of modern Felidae: a genetic assessment. Science 2006, 311:73-77.
55. Jolly C., Booth N.J., Neil S.J.D. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2 mediated restriction in T cells. J. Virol. 2010, 84:12185-12199.
56. Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y., McNatt M., Hatziioannou T., Bieniasz P.D. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 2009, 83:1837-1844.
57. Kaletsky R.L., Francica J.R., Agrawal-Gamse C., Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2886-2891.
58. Keckesova Z., Ylinen L.M., Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10780-10785.
59. Klimkait T., Strebel K., Hoggan M.D., Martin M.A., Orenstein J.M. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 1990, 64:621-629.
60. Kupzig S., Korolchuk V., Rollason R., Sudgen A., Wilde A., Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4:694-709.
61. Langelier C.R., Sandrin V., Eckert D.M., Christensen D.E., Chandrasekaran V., Alam S.L., Aiken C., Olsen J.C., Kar A.K., Sodroski J.G., Sundquist W.I. Biochemical characterization of a recombinant TRIM5α protein that restricts human immunodeficiency virus type 1 replication. J. Virol. 2008, 82:11682-11694.
62. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003, 300:1112.
63. Le Tortorec A., Neil S.J. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 2009, 83:11966-11978.
64. Li X.Y., Guo F., Zhang L., Kleiman L., Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 2007, 282:32065-32074.
65. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 2004, 14:1385-1391.
66. Liu Y.J. IPC: professional type I interferon producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
67. Liu B., Yu X., Luo K., Yu Y., Yu X.F. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 2004, 78:2072-2081.
68. Löchelt M., Romen F., Bastone P., Muckenfuss H., Kirchner N., Kim Y.B., Truyen U., Rosler U., Battenberg M., Saib A., Flory E., Cichutek K., Münk C. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7982-7987.
69. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 2007, 81:7238-7248.
70. Malim M.H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B 2009, 364:675-687.
71. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
72. Mangeat B., Gers-Huber G., Lehmann M., Zufferey M., Luban J., Piguet V. HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009, 5:e1000574.
73. Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V., Thomas D., Strebel K., Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1998, 1:565-574.
74. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9:1398-1403.
75. Masuyama N., Kuronita T., Tanaka R., Muto T., Hirota Y., Takigawa A., Fujita H., Aso Y., Amano J., Tanaka Y. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 2009, 284:15927-15941.
76. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 2007, 81:7099-7110.
77. McEwan W.A., Schaller T., Ylinen L.M., Hosie M.J., Towers G.J., Willett B.J. Truncation of TRIM5 in Feliformia explains the absence of retroviral restriction in cells of the domestic cat. J. Virol. 2009, 83:8270-8275.
78. McNatt M.W., McNatt M.W., Zang T., Hatziioannou T., Bartlett M., Fofana I.B., Johnson W.E., Neil S.J., Bieniasz P.D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 2009, 5:e1000300.
79. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 2004, 279:7792-7798.
80. Mehle A., Goncalves J., Santa-Marta M., McPike M., Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004, 18:2861-2866.
81. Miller R.J., Cairns J.S., Bridges S., Sarver N. Human immunodeficiency virus and AIDS: insights from animal lentiviruses. J. Virol. 2000, 74:7187-7195.
82. Mische C.C., Javanbakht H., Song B., Diaz-Griffero F., Stremlau M., Strack B., Si Z., Sodroski J. Retroviral restriction factor TRIM5alpha is a trimer. J. Virol. 2005, 79:14446-14450.
83. Mitchell R.S., Katsura C., Skasko M.A., Fitzpatrick K., Lau D., Ruiz A., Stephens E.B., Margottin-Goguet F., Benarous R., Guatelli J.C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via b-TrCP and endo-lysosomal trafficking. PLoS Pathog. 2009, 5:e1000450.
84. Miyagi E., Andrew A.J., Kao S., Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2868-2873.
85. Miyakawa K., Ryo A., Murakami T., Ohba K., Yamaoka S., Fukuda M., Guatelli J., Yamamoto N. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog. 2009, 5:e1000700.
86. Münk C., Beck T., Zielonka J., Hotz-Wagenblatt A., Chareza S., Battenberg M., Thielebein J., Cichutek K., Bravo I.G., O'Brien S.J., Löchelt M., Yuhki N. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 2008, 9:R48.
87. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
88. Neil S.J., Eastman S.W., Jouvenet N., Bieniasz P.D. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2006, 2:e39.
89. Neil S.J., Sandrin V., Sundquist W.I., Bieniasz P.D. An interferon-alpha induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2:193-203.
90. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
91. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15:166-170.
92. Ohtomo T., Sugamata Y., Ozaki Y., Ono K., Yoshimura Y., Kawai S., Koishihara Y., Ozaki S., Kosaka M., Hirano T., Tsuchiya M. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 1999, 258:583-591.
93. Opi S., Takeuchi H., Kao S., Khan M.A., Miyagi E., Goila-Gaur R., Iwatani Y., Levin J.G., Strebel K. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 2006, 80:4673-4682.
94. Pedersen N.C. The feline immunodeficiency virus. The Retroviridae 1993, vol. 2:181-228. Plenum Press, New York, NY.
95. Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency syndrome. Science 1987, 235:790-793.
96. Pedersen N.C., Yamamoto J.K., Ishida T., Hansen H. Feline immunodeficiency virus infection. Vet. Immunol. Immunopathol. 1989, 21:111-129.
97. Poeschla E.M., Wong-Staal F., Looney D.J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 1998, 4:354-357.
98. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139:499-511.
99. Reeves R.H., O'Brien S.J. Molecular genetic characterization of the RD-114 gene family of endogenous feline retroviral sequences. J. Virol. 1984, 52:164-171.
100. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., Ballabio A. The tripartite motif family identifies cell compartments. EMBO J. 2001, 20:2140-2151.
101. Rollason R., Korolchuk V., Hamilton C., Schu P., Banting G. Clathrin-mediated endocytosis of a lipid-raft associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 2007, 120:3850-3858.
102. Rong L., Zhang J., Lu J., Pan Q., Lorgeoux R.P., Aloysius C., Guo F., Liu S.L., Wainberg M.A., Liang C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 2009, 83:7536-7546.
103. Sakai H., Shibata R., Sakuragi J., Sakuragi S., Kawamura M., Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 1993, 67:1663-1666.
104. Sakuma T., Noda T., Urata S., Kawaoka Y., Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 2009, 83:2382-2385.
105. Sauter D., Schindler M., Specht A., Landford W.N., Münch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6:409-421.
106. Sebastian S., Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2005, 2:40.
107. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
108. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9:1404-1407.
109. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., Willett B.J. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004, 303:1192-1195.
110. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 2003, 278:44412-44416.
111. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
112. Simons K., Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000, 1:31-39.
113. Sova P., Volsky D.J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 1993, 67:6322-6326.
114. Sparger E.E., Luciw P.A., Elder J.H., Yamamoto J.K., Lowenstine L.J., Pedersen N.C. Feline immunodeficiency virus is a lentivirus associated with an AIDS-like disease in cats. AIDS 1989, 3(Suppl. 1):S43-S49.
115. Stern M.A., Hu C., Saenz D.T., Fadel H.J., Sims O., Peretz M., Poeschla E.M. Productive replication of Vif-chimeric HIV-1 in feline cells. J. Virol. 2010, 84:7378-7395.
116. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12:591-601.
117. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987, 328:728-730.
118. Strebel K., Klimkait T., Martin M.A. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988, 241:1221-1223.
119. Strebel K., Klimkait T., Maldarelli F., Martin M.A. Molecular and biochemical analyses of human immunodeficiency virus type 1 Vpu protein. J. Virol. 1989, 63:3784-3791.
120. Stremlau M., Owens C.M., Perron M.G., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5 alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853.
121. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5514-5519.
122. Teng B., Burant C.F., Davidson N.O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993, 260:1816-1819.
123. Terwilliger E.F., Cohen E.A., Lu Y.C., Sodroski J.G., Haseltine W.A. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:5163-5167.
124. Tompkins M.B., Tompkins W.A. Lentivirus-induced immune dysregulation. Vet. Immunol. Immunopathol. 2008, 123:45-55.
125. Torten M., Franchini M., Barlough J.E., George J.W., Mozes E., Lutz H., Pedersen N.C. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J. Virol. 1991, 65:2225-2230.
126. Towers G.J. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007, 4:40.
127. Troyer J.L., Pecon-Slattery J., Roelke M.E., Black L., Packer C., O'Brien S.J. Patterns of feline immunodeficiency virus multiple infection and genome divergence in a free-ranging population of African lions. J. Virol. 2004, 78:3777-3791.
128. Troyer J.L., Pecon-Slattery J., Roelke M.E., Johnson W., VandeWoude S., Vazquez-Salat N., Brown M., Frank L., Woodroffe R., Winterbach C., Winterbach H., Hemson G., Bush M., Alexander K.A., Revilla E., O'Brien S.J. Seroprevalence and genomic divergence of circulating strains of feline immunodeficiency virus among Felidae and Hyaenidae species. J. Virol. 2005, 79:8282-8294.
129. Troyer J.L., Vandewoude S., Pecon-Slattery J., McIntosh C., Franklin S., Antunes A., Johnson W., O'Brien S.J. FIV cross-species transmission: an evolutionary prospective. Vet. Immunol. Immunopathol. 2008, 123:159-166.
130. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252.
131. VandeWoude S., Apetrei C. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin. Microbiol. Rev. 2006, 19:728-762.
132. Varthakavi V., Smith R.M., Bour S.P., Strebel K., Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15154-15159.
133. Vidal-Laliena M., Romero X., March S., Requena V., Petriz J., Engel P. Characterization of antibodies submitted to the B cell section of the 8th Human leukocyte differentiation antigens workshop by flow cytometry and immunohistochemistry. Cell Immunol. 2005, 236:6-16.
134. Willett B.J., Flynn J.N., Hosie M.J. FIV infection of the domestic cat: an animal model for AIDS. Immunol. Today 1997, 18:182-189.
135. Willey R.L., Maldarelli F., Martin M.A., Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 1992, 66:7193-7200.
136. Wolf D., Goff S.P. Host restriction factors blocking retroviral replication. Annu. Rev. Genet. 2008, 42:143-163.
137. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7465-7470.
138. Yamamoto J.K., Sparger E., No E.W., Andersen P.R., O'Connor T.P., Handell C.P., Lowenstine L., Munn R., Pedersen N.C. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am. J. Vet. Res. 1988, 49:1246-1258.
139. Yamamoto J.K., Hansen H., Ho E.W., Morishita T.Y., Okuda T., Saura T.R., Nakamura R.M., Pedersen N.C. Epidemiologic and clinical aspects of FIV infection in cats from the continental U.S. and Canada and possible mode of transmission. J. Am. Vet. Med. Assoc. 1989, 194:213-220.
140. Yamauchi K., Wada K., Tanji K., Tanaka M., Kamitani T. Ubiquitination of E3 ubiquitin ligase TRIM5α and its potential role. FEBS J. 2008, 275:1540-1555.
141. Yang Y., Guo F., Cen S., Kleiman L. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 2007, 365:92-100.
142. Yang S.Y., Lopez L.A., Hauser H., Exline C.M., Haworth K.G., Cannon P.M. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 2010, 7:13.
143. Yee J.K., Miyanohara A., La Porte P., Bouic K., Burns J.C., Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9564-9568.
144. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
145. Yu Y., Xiao Z., Ehrlich E.S., Yu X., Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004, 18:2867-2872.
146. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
147. Zhang F., Wilson S.J., Landford W.C., Virgen B., Gregory D., Johnson M.C., Munch J., Kirchhoff F., Bieniasz P.D., Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6:54-67.
148. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:6073-6076.
149. Zielonka J., Marino D., Hofmann H., Yuhki N., Löchelt M., Münk C. Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids. J. Virol. 2010, 84:7312-7324.